DexCom, Inc. $DXCM Stock Holdings Increased by Strs Ohio

Strs Ohio lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 6.4% in the second quarter, Holdings Channel.com reports. The firm owned 238,946 shares of the medical device company’s stock after acquiring an additional 14,346 shares during the quarter. Strs Ohio’s holdings in DexCom were worth $20,858,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Golden State Wealth Management LLC lifted its position in shares of DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after purchasing an additional 264 shares in the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of DexCom in the first quarter worth approximately $27,000. Anderson Financial Strategies LLC bought a new position in DexCom during the first quarter valued at approximately $37,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in DexCom during the second quarter valued at approximately $45,000. Finally, Private Trust Co. NA raised its position in DexCom by 99.4% during the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock valued at $46,000 after acquiring an additional 335 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on DXCM shares. Morgan Stanley raised their price objective on shares of DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. UBS Group raised their price objective on shares of DexCom from $105.00 to $106.00 and gave the company a “buy” rating in a research report on Thursday, July 31st. Argus started coverage on shares of DexCom in a research report on Thursday, August 21st. They set a “buy” rating and a $100.00 price objective on the stock. Royal Bank Of Canada cut their price objective on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating on the stock in a research report on Friday. Finally, BTIG Research cut their price objective on shares of DexCom from $109.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $91.65.

DexCom Trading Down 14.6%

Shares of DXCM stock opened at $58.22 on Friday. DexCom, Inc. has a 12 month low of $56.44 and a 12 month high of $93.25. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The business’s 50 day moving average is $70.94 and its two-hundred day moving average is $77.90. The company has a market cap of $22.83 billion, a PE ratio of 40.43, a price-to-earnings-growth ratio of 1.43 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. During the same quarter last year, the company posted $0.45 earnings per share. The company’s revenue for the quarter was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 1,466 shares of the firm’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the sale, the executive vice president owned 105,223 shares in the company, valued at approximately $8,417,840. This trade represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the firm’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the completion of the sale, the director owned 51,121 shares in the company, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 5,383 shares of company stock worth $434,274. Insiders own 0.32% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.